title: [Primary prevention of cervical cancer].
abstract: Cervical cancer is a global public health problem related to infection by human papilloma virus. Countries with organized programs for detection and treatment of precancerous lesions and cervical cancer prevent 80% of cases; however, prevention-based cytology, colposcopy and treatment of injuries is effective but still expensive, invasive and nonspecific, especially in developing countries. The goal of primary prevention through immunization against human papillomavirus is with the use of quadrivalent vaccine genotypes 6, 11, 16 and 18 and bivalent genotypes 16 and 18, which are produced using recombinant technology. These are effective in patients without prior exposure to viral genotypes, mainly when they have not initiated sexual activity. Recommended ages are 9 to 13 years and vaccine is administered through school health centers or community centers who promote informational campaigns and dissemination aimed at parents who request this. Screening programs for cervical cancer are limited and only oncogenic virus immunization will reduce their frequency, saving the lives of hundreds of women worldwide.
authors: Dirección de Investigación y Enseñanza, Hospital Juárez de México, México, D.F., Mexico. vvargashernandez@yahoo.com.mx
authors: Víctor Manuel
authors: VM
authors: Vargas-Hernández
authors: Gustavo
authors: G
authors: Acosta-Altamirano
mesh_terms: D005260:Female; D006801:Humans; D030361:Papillomavirus Infections / Q000150:complications* / Q000517:prevention & control*; D053918:Papillomavirus Vaccines; D011322:Primary Prevention; D002583:Uterine Cervical Neoplasms / Q000517:prevention & control* / Q000821:virology*
chemical_list: D053918:Papillomavirus Vaccines